Drug Trial Radar · NCT04692688
Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy
Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
103
Actual
Start
Apr 8, 2021
Primary completion
Jan 25, 2023
Study completion Jan 25, 2023
Sponsor
- Lead sponsor
- Opus Genetics, IncIndustry
- Sponsor type
- Industry
- First posted
- Jan 5, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the safety and efficacy of APX3330 to treat diabetic retinopathy (DR) and diabetic macular edema (DME).
Conditions
- Diabetic Retinopathy
- Diabetic Macular Edema
- NPDR - Non Proliferative Diabetic Retinopathy
- PDR - Proliferative Diabetic Retinopathy
Interventions
APX3330Drug
APX3330, a small-molecule oral tablet, is a Ref-1 inhibitor that can potentially reduce proinflammatory and hypoxic signaling that contributes to several eye diseases.
PlaceboDrug
Placebo tablets are identical to APX3330 tablets except for the absence of the active pharmaceutical ingredient.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent of Subjects With ≥ 2-step Improvement in Diabetic Retinopathy Severity Score (DRSS)Time frame: 24 Weeks
Locations
24 sites in 1 country. Site status is shown where the registry gives one.
Clinical Site 9
Phoenix, Arizona
Clinical Site 8
Bakersfield, California
Clinical Site 5
Beverly Hills, California
Clinical Site 11
Palm Desert, California
Clinical Site 2
Sacramento, California
Clinical Site 24
Walnut Creek, California
Clinical Site 19
Miami, Florida
Clinical Site 7
Winter Haven, Florida
Clinical Site 6
Carmel, Indiana
Clinical Site 14
Hagerstown, Maryland
Clinical Site 22
Springfield, Massachusetts
Clinical Site 17
Grand Blanc, Michigan
Clinical Site 12
Albuquerque, New Mexico
Clinical Site 15
Shirley, New York
Clinical Site 20
Charlotte, North Carolina
Clinical Site 1
Rapid City, South Dakota
Clinical Site 18
Austin, Texas
Clinical Site 16
Bellaire, Texas
Clinical Site 10
Fort Worth, Texas
Clinical Site 4
McAllen, Texas
Clinical Site 3
San Antonio, Texas
Clinical Site 23
San Antonio, Texas
Clinical Site 13
Southlake, Texas
Clinical Site 21
Ogden, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.